ImuVeo Information

At imuveo, we are advancing precision radiopharmaceutical science to transform cancer care. We develop CD2 targeted radiopharma across two complementary programmes: • Therapy monitoring Our CD2 targeted imaging agents provide clinicians with actionable, immune-centric insights into how patients are responding to immunotherapy. By making T cell dynamics visible in real time, we help improve treatment decisions and individualize care. • Theranostic We are building CD2 targeted theranostic radioligand therapies designed to precisely deliver therapeutic radiation to T cell driven malignancies. This approach harnesses the specificity of CD2 targeting to maximize anti-tumor effects while limiting off-target toxicity. imuveo has advanced lead tracers into the clinic, generating first human data that demonstrate safety, target engagement, and potential for impact in oncology. Our radiopharmaceutical platform is positioned to support both better therapy decision making and next-generation targeted therapy options across immuno-oncology.